Publications by authors named "Fumitaka Nishimae"

Oncolytic adenoviruses (OAds), most of which are based on species C human adenovirus serotype 5 (Ad5) (OAd5), have recently received much attention as potential anticancer agents. High seroprevalence of anti-Ad5 neutralizing antibodies is a major hurdle for Ad5-based gene therapy. However, the impacts of anti-Ad5 neutralizing antibodies on OAd5-mediated transgene expression in the tumor and antitumor effects remain to be fully elucidated.

View Article and Find Full Text PDF
Article Synopsis
  • * A study screened 1,134 FDA-approved drugs and found that domperidone, a drug typically used for nausea, significantly increased OAd replication in human tumor cells.
  • * Domperidone enhanced the antitumor effects by boosting E1A mRNA levels related to OAd replication, but it acted on a different target than its known D2 receptor, suggesting new avenues for cancer therapy.
View Article and Find Full Text PDF

Background/aim: Efficient production of adenovirus vectors is crucial for their clinical use. Adenovirus death protein (ADP), which is encoded in the E3 region of the adenovirus genome, is involved in host-cell lysis and the subsequent release of progeny virus; however, the ADP gene is often removed from the adenovirus vector genome.

Materials And Methods: We have developed adenovirus vectors that possess the ADP gene and maintain a relatively large insertion capacity for foreign genes by deleting the partial E3 region.

View Article and Find Full Text PDF
Article Synopsis
  • Replication-incompetent adenovirus (Ad) vectors are promising for gene delivery to liver cells (hepatocytes) but can cause liver toxicity due to uncontrolled gene expression.
  • Researchers developed a modified Ad vector with sequences that target liver-specific microRNA miR-122a to reduce this toxicity, showing success in mouse models.
  • In their study, the modified Ad vector demonstrated higher gene expression and lower cytotoxicity in human hepatocytes compared to conventional Ad vectors, indicating its potential as a safer gene delivery option.
View Article and Find Full Text PDF

Background/aim: Oncolytic adenoviruses (OAds) have attracted much attention as novel anticancer therapeutics. The proper design of an expression cassette containing the E1A gene, which is indispensable for self-replication of the Ad genome, is crucial for efficient tumor cell-specific infection of an OAd. Various types of oncolytic adenoviruses (OAds) possessing different types of the E1A gene expression cassettes have been developed, but their oncolytic activities and safety profiles have not been systematically evaluated.

View Article and Find Full Text PDF

Adenovirus (Ad) vector-mediated transduction can cause hepatotoxicity during two phases, at ∼2 and 10 days after administration. Early hepatotoxicity is considered to involve inflammatory cytokines; however, the precise mechanism remains to be clarified. We examined the mechanism of early Ad vector-induced hepatotoxicity by using a conventional Ad vector, Ad-CAL2, and a modified Ad vector, Ad-E4-122aT-CAL2.

View Article and Find Full Text PDF

Clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR associated proteins (Cas) 9 system is a powerful tool for genome editing and still being aggressively improved. Cas12a, a recently discovered Cas9 ortholog, is expected to become complementary to Cas9 due to its unique characteristics. Previously we attempted to establish an adenovirus (Ad) vector-mediated delivery of CRISPR-Cas12a system since Ad vector is widely used for gene transfer in basic researches and medical applications.

View Article and Find Full Text PDF